An analysis of Medtronic MiniMed 670G insulin pump use in clinical practice and the impact on glycemic control, quality of life, and compliance

This study evaluated the use of the Medtronic MiniMed 670G system in adults with type 1 diabetes mellitus from a large endocrinology practice and its impact on glycemic control, quality of life (QoL), compliance and safety. 84 participants completed one site visit for data collection. Percentage of...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes research and clinical practice 2021-07, Vol.177, p.108876-108876, Article 108876
Main Authors: Horowitz, Maxwell E., Kaye, William A., Pepper, Gary M., Reynolds, Kathryn E., Patel, Shital R., Knudson, Kort C., Kale, Geetanjali K., Gutierrez, Maria E., Cotto, Leslie A., Horowitz, Barry S.
Format: Article
Language:English
Subjects:
Compliance
Diabetes Mellitus Type 1
Glycemic Control
Medtronic MiniMed 670G Insulin Pump
Quality of Life
Time in Range
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study evaluated the use of the Medtronic MiniMed 670G system in adults with type 1 diabetes mellitus from a large endocrinology practice and its impact on glycemic control, quality of life (QoL), compliance and safety. 84 participants completed one site visit for data collection. Percentage of time in range (TIR: 70–180 mg/dL), hyperglycemia or time above range (TAB) (>180 mg/dL), hypoglycemia or time below range (TBR) (
ISSN:0168-8227
1872-8227
DOI:10.1016/j.diabres.2021.108876